Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline administration methods to prevent ovarian hyperstimulation syndrome in women with polycystic ovary syndrome
IRCT20090526001952N16Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cabergoline in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Tehran University of Medical Sciences. Started Mar 2023; status: completed.
02
Drugs
cabergoline
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on IRCT20090526001952N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090526001952N16.